JaeHongParkMD

Hematologic Oncology

Assistant Attending Physician, Memorial Sloan Kettering Cancer Center; Assistant Professor of Medicine, Weill Cornell Medical College

Request Appointment

Overview of Dr. Park

Dr. Jae Park is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Johns Hopkins University School of Medicine and has been in practice 12 years. Dr. Park accepts several types of health insurance, listed below. He is one of 497 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
530 East 74th Street
New York, NY 10021
Book by Phone+1(719) 266-3590

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
Massachusetts General HospitalResidency, Internal Medicine, 2005 - 2008
Johns Hopkins University School of MedicineClass of 2005

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2008 - 2025
CT State Medical License 2023 - 2024
NH State Medical License 2024 - 2024
NC State Medical License 2020 - 2022
ME State Medical License 2021 - 2021
OK State Medical License 2021 - 2021
MA State Medical License 2007 - 2010
Join now to see all

Clinical Trials

Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 Start of enrollment: 2010 Jan 05
Active, not recruiting
Phase 1
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy Start of enrollment: 2011 Jul 01
Completed
Phase 2
Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab Start of enrollment: 2011 Aug 22
Completed
Phase 1
BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia Start of enrollment: 2012 Oct 01
Active, not recruiting
Phase 2
Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) Start of enrollment: 2015 Aug 21
Terminated
Phase 2
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies Start of enrollment: 2017 Mar 15
Active, not recruiting
Phase 1
A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia Start of enrollment: 2018 Feb 09
Active, not recruiting
Phase 2
A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy Start of enrollment: 2019 Oct 30
Active, not recruiting
Phase 2
The Combination of Venetoclax and Obinutuzumab in People With Chronic Lymphocytic Leukemia (CLL) Start of enrollment: 2020 Dec 03
Active, not recruiting
Phase 2
19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers Start of enrollment: 2020 Jul 06
Active, not recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of Venetoclax in Combination With Chemotherapy to Treat Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2022 Jun 16
Active, not recruiting
Early Phase 1
Roles: Contact, Principal Investigator
Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma Start of enrollment: 2023 Feb 23
Recruiting
Phase 1
Roles: Principal Investigator, Contact
A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia Start of enrollment: 2024 Apr 18
Recruiting
Phase 1
Roles: Contact, Principal Investigator
A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia Start of enrollment: 2023 Aug 22
Recruiting
Phase 1
Roles: Contact
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2024 Feb 23
Recruiting
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

1 citations
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10
Metabolic Tumor Volume Response after Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma.
Harper Hubbeling, Doris Leithner, Emily A Silverman, Jessica Flynn, Sean Devlin
Clinical Cancer Research. 2024-11-15
HMA/VEN treatment modifications and associated outcomes in-mutant AML.
Kuo-Kai Chin, Andriy Derkach, Christopher Famulare, Gaurav K Gupta, P Dayand Borge
Leukemia & Lymphoma. 2024-10-14

Abstracts/Posters

Evaluation of Biomarkers As Predictors of Blinatumomab Toxicity and Real-World Management of Blinatumomab Toxicity in B-Acute Lymphoblastic Leukemia Patients
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pegaspargase Can Safely be Administered in Adults Age 40 and Older with Acute Lymphoblastic Leukemia
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Inotuzumab Ozogamicin Is an Effective Salvage Therapy in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia with High-Risk Molecular Features, Including TP53 Loss
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Treatment Outcomes with Purine Nucleoside Analog Alone or with Rituximab for Hairy Cell Leukemia Patients at First Relapse: A Multi-Center Outcomes Analysis
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
MSKCC Early Experience Using Radiotherapy As a Bridging Strategy for Relapsed Diffuse Large B Cell Lymphoma before CD19 CAR T Therapy
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Easix and Modified-Easix Are Early Predictors of Severe Cytokine Release Syndrome and Neurotoxicity in Patients Treated with Chimeric Antigen Receptor T Cells
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Management of CAR T-Cell Toxicities: Concordance and Divergence between Healthcare Providers and Expert Consensus Recommendations
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Comparing Gradings of Immune Effector Cells Toxicities: Application of Astct Consensus Grading System and Implications for Clinical Management
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Early Experience Using Radiotherapy As a Salvage Treatment for Relapsed or Refractory Non-Hodgkin Lymphomas Following CD19 Chimeric Antigen Receptor Modified T-Cell Th...
Jae H. Park, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Clinical Factors Associated with Improved Survival Following Allogeneic HSCT after CD19 CAR Therapy in Adult Patients with Relapsed B-ALL
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
First Line Chemo-Free Therapy with the BRAF Inhibitor Vemurafenib Combined with Obinutuzumab Is Effective in Patients with Hcl
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Advances in CAR T-Cell Therapy for Leukemia, Lymphoma, and Myeloma: Where We Are and Where We Are Going
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies
60th American Society of Hematology Annual Meeting - 11/30/2018
CAR-T Cell Therapy and Stem Cells in Acute Lymphoblastic Leukemia
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Join now to see all

Press Mentions

How Do Gut Microbes Affect the Success of CAR T Immunotherapy?March 17th, 2022
Pediatric-Inspired Pegaspargase Regimen Shows Promise for Treatment of ALL/LBLDecember 1st, 2020
CAR-T Therapy Makes Early Inroads in Treating Brain CancerDecember 29th, 2016
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Texas BlueChoice
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment